Will it change anything?
Yesterday MiniMed announced FDA approval of their newest system the MiniMed Flex. The system has many positive aspects and its design meets the new realities of the insulin pump market. With smartphone control and no screen on the pump itself the Flex carries with it a lower cost of goods. Like the Mobii from Tandem MiniMed can also send updates directly to the smartphone another cost saving move. The question...
Just the facts PLEASE
Before I begin today let me state this is a post I am actually encouraging everyone to share. The entire diabetes community needs to hear this. In yesterday’s post we discussed how the diabetes world is going nuts over the results of a study that generated a poster at ATTD. Breakthrough Type 1 UK posted this on Facebook. “Sana Biotechnology shared new data at the Advanced Technologies & Treatments for Diabetes (ATTD)...
More Shenanigans
It never ceases to amaze me the shenanigans that go on in our wacky world. Here are some recent examples. Breakthrough Type 1 UK posted this on Facebook. “Sana Biotechnology shared new data at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, showing that their lab-engineered, insulin-producing cells have survived in one person for 14 months without the need for immunosuppression” Yep that sure sound exciting until you consider the...
All That Jazz
With ATTD in the books our wacky world now sets our sights on New Orleans and the annual ADA money grab come June. Did we learn anything of substance from ATTD? Not really. Will New Orleans be any different? Probably not. This does not however mean we are lacking for news. 1. Insulet announces a recall. Other than seeing their share price decline almost 7% recalls are SOP for the insulin...
Well the geeks are happy
With ATTD in full swing a few trends have emerged. Everyone is trying to position themselves as the savior for patients with Type 2. The fascination with a fully closed loop insulin delivery systems continues. While Abbott is spending a boatload of bucks in a desperate attempt to differentiate the Libre platform from the Dexcom platform. Let’s take the last item first as it’s the perfect example of trying to create...
It’s no longer about the toys in the toy chest
As our wacky world gathers in Barcelona for this year’s installment of ATTD, the ultimate toy fair as its all about way cool whiz bang. Like almost every conference these days it’s an opportunity for everyone to show their wares and explain why their toy is better than sliced bread and soft soap. It’s also another opportunity for the newbies to raise money as they too will tell potential investors...
The patient can be saved
In spite of how the executives feel at MiniMed in the real world not lala land the IPO was an unmitigated disaster. The funny perhaps ironic thing is this company can be saved. Now I’ll preface that remark as it can only be saved with a new management team. The current team is not capable has zero talent and frankly no interest in saving the company. If this team remains...